Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06903065 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

A Phase 1 study of MASH, sponsored by Hoffmann-La Roche.

Active
Registry status
Phase 1
Development phase
50
Enrollment target
20
Study locations

NCT06903065 is a Phase 1 study of MASH that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 50 participants, below the 156-participant average among 5 other MASH trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06903065, a Phase 1 study of MASH, is active but no longer recruiting, sponsored by Hoffmann-La Roche.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.

Conditions Studied

MASH

Interventions

  • DRUG RO7790121

Study Locations (20)

Texas

  • Pinnacle Clinical Research - Austin - Austin
  • Bellaire Clinical Research, LLC - Bellaire
  • DHR Health Institute for Research and Development - Edinburg
  • Pinnacle Clinical Research Georgetown - Georgetown
  • Pinnacle Clinical Research, PLLC - San Antonio
  • GI Alliance - Southlake

Tennessee

  • Innovative Clinical Research - Clarksville
  • Gastroenterology Center of the MidSouth PC - Cordova

Jalisco

  • Centro de Investigacion Clinica y Medicina Traslacional CIMeT - Guadalajara
  • Hospital General de Occidente SSJ - Zapopan

Mexico CITY (federal District)

  • Inovacion y Desarrollo en ciencias de la salud - Ciudad de Mxico
  • Centro de Investigacion y Gastroenterologia - Mexico City

Arizona

  • Adobe Clinical Research, LLC - Tucson

Florida

  • Gastro Health Research - Miami - Miami

Georgia

  • Gastrointestinal Specialists of Georgia, PC - Marietta

Louisiana

  • Delta Research Partners, LLC (Bastrop) - Bastrop

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-04-14
Est. Completion 2026-12-30
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06903065

The ClinicalTrials.gov registry entry for NCT06903065 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 5 other MASH trials with a reported enrollment target (68% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with MASH appearing as the primary indexed condition, and to 1 intervention - of which RO7790121 is the first listed.

NCT06903065 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, Tennessee, Jalisco.

Frequently Asked Questions

What is clinical trial NCT06903065 about?

NCT06903065 is a clinical study titled "A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis". The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.

What is the current status of trial NCT06903065?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-04-14. Estimated completion is 2026-12-30.

What conditions does trial NCT06903065 study?

This clinical trial studies the following conditions: MASH.

What interventions are being tested in trial NCT06903065?

The interventions under investigation include: RO7790121 (DRUG).

Who is sponsoring clinical trial NCT06903065?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06903065 being conducted?

This trial has 20 study locations across Arizona, Florida, Georgia, Louisiana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for MASH

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

MASH

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.